Verismo Therapeutics Raises $17M in Second Pre-Series A Funding
Summary
Verismo Therapeutics, a Philadelphia, PA-based clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, raised $17M in a second pre-Series A financing round. The company, which has secured a total of $50M in financing since launching in 2020, intends to use the financing for continued advancement of the clinical trial for SynKIR™-110, a first-in-class KIR-CAR T cell immunotherapy candidate for solid tumors, and pre-clinical development of SynKIR™-310, a KIR-CAR T cell immunotherapy therapeutic for blood cancers. Verismo Therapeutics is a pioneer in dual-chain KIR-CAR technology, and its lead asset, SynKIR™-110, is currently undergoing first-in-human Phase 1 clinical trial. The company is developing the KIR-CAR T cell platform, a modified NK-like receptor designed to improve persistence and efficacy against aggressive solid tumors. The KIR-CAR T cell platform technology was developed specifically for advanced solid tumors, an area of high unmet medical need.
Funding
Review available funding amount, funding date, investors, and linked company information related to Verismo Therapeutics Raises $17M in Second Pre-Series A Funding in the interactive ISVWorld profile.